The HLA-II immunopeptidome of SARS-CoV-2
Published version of a preprint
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently the same group has investigated the HLA-DR class II immunopeptidome of infected A549 and HEK293 cells showing a strong bias towards the presentation of viral structural proteins (M, N, S)25.”
From Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887 · cited 1×
“…various assays including ELISpot, Intracellular Cytokine Staining (ICS) and Activation Induced Markers (AIM) (Figure 3A) (Keller et al., 2020; Le Bert et al., 2020, 2021; Mahajan et al., 2021; Mateus et al., 2020; Nelde et al., 2021; Peng et al., 2020; Prakash et al., n.d.; Tarke et al., 2021).”
MethodAdaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179 · cited 2×
“This dataset combines 9 studies that tested CD4+ T cell responses using various assays including ELISpot, Intracellular Cytokine Staining (ICS) and Activation Induced Markers (AIM) (Figure 3A) (Keller et al., 2020; Le Bert et al., 2020, 2021; Mahajan et al., 2021; Mateus et al., 2020; Nelde et al., 2021; Peng et al.,…”
MethodSelective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120 · cited 6×
“…at T cell responses to peptides from all annotated viral proteins and found significant responses to both structural and non-structural proteins (Ferretti et al., 2020; Gangaev et al., 2021; Kared et al., 2021; Mateus et al., 2020; Nelde et al., 2021; Prakash et al., 2021; Tarke et al., 2021).”
BackgroundMethodInfluentialBNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00808-x · Cited by 582
Tarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540
Research works printed but not linked: 63
- Wherry, 2022, T cell immunity to COVID-19 vaccines, Science, 377, 821, 10.1126/science.add2897 · DOI · Paper page
- Pardi, 2018, mRNA vaccines — a new era in vaccinology, Nat. Rev. Drug Discov., 17, 261, 10.1038/nrd.2017.243 · DOI · Paper page
- Neale, 2023, CD4+ and CD8+ T Cell and Antibody Correlates of Protection against Delta Vaccine Breakthrough Infection: A Nested Case-Control Study within the PITCH Study, medRxiv
- Martínez-Flores, 2021, SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants, Front. Immunol., 12, 701501, 10.3389/fimmu.2021.701501 · DOI · Paper page
- Oronsky, 2022, Nucleocapsid as a next-generation COVID-19 vaccine candidate, Int. J. Infect. Dis., 122, 529, 10.1016/j.ijid.2022.06.046 · DOI
- Dutta, 2020, The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development, J. Virol., 94, e00647-20, 10.1128/JVI.00647-20 · DOI · Paper page
- Arieta, 2023, The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection, Cell, 186, 2392, 10.1016/j.cell.2023.04.007 · DOI · Paper page
- Matchett, 2021, Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity, J. Immunol., 207, 376, 10.4049/jimmunol.2100421 · DOI · Paper page
- Chen, 2021, T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research, J. Cell Mol. Med., 25, 1274, 10.1111/jcmm.16200 · DOI
- Keller, 2020, SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein, Blood, 136, 2905, 10.1182/blood.2020008488 · DOI · Paper page
- Joag, 2021, Cutting Edge: Mouse SARS-CoV-2 Epitope Reveals Infection and Vaccine-Elicited CD8 T Cell Responses, J. Immunol., 206, 931, 10.4049/jimmunol.2001400 · DOI
- Lee, 2021, Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity, J. Virol., 95, 10.1128/JVI.02002-20 · DOI
- Mahajan, 2021, Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals, Sci. Rep., 11, 10.1038/s41598-021-92521-4 · DOI
- Nielsen, 2021, SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity, EBioMedicine, 68, 10.1016/j.ebiom.2021.103410 · DOI
- Rha, 2021, PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19, Immunity, 54, 44, 10.1016/j.immuni.2020.12.002 · DOI · Paper page
- Shomuradova, 2020, SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors, Immunity, 53, 1245, 10.1016/j.immuni.2020.11.004 · DOI · Paper page
- Ferretti, 2020, Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein, Immunity, 53, 1095, 10.1016/j.immuni.2020.10.006 · DOI · Paper page
- Kared, 2021, SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals, J. Clin. Invest., 131, 10.1172/JCI145476 · DOI · Paper page
- Prakash, 2021, Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines, J. Immunol., 206, 2566, 10.4049/jimmunol.2001438 · DOI · Paper page
- Finkel, 2020, The Coding Capacity of SARS-CoV-2, bioRxiv
- Abelin, 2017, Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
- Bassani-Sternberg, 2016, Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions, J. Immunol., 197, 2492, 10.4049/jimmunol.1600808 · DOI · Paper page
- Chong, 2018, High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome, Mol. Cell. Proteomics, 17, 533, 10.1074/mcp.TIR117.000383 · DOI · Paper page
- Sarkizova, 2020, A large peptidome dataset improves HLA class I epitope prediction across most of the human population, Nat. Biotechnol., 38, 199, 10.1038/s41587-019-0322-9 · DOI · Paper page
- Croft, 2013, Kinetics of antigen expression and epitope presentation during virus infection, PLoS Pathog., 9, 10.1371/journal.ppat.1003129 · DOI · Paper page
- McMurtrey, 2008, Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes, Proc. Natl. Acad. Sci. USA, 105, 2981, 10.1073/pnas.0711874105 · DOI
- Rucevic, 2016, Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses, J. Virol., 90, 8605, 10.1128/JVI.00599-16 · DOI
- Schellens, 2015, Measles Virus Epitope Presentation by HLA: Novel Insights into Epitope Selection, Dominance, and Microvariation, Front. Immunol., 6, 546, 10.3389/fimmu.2015.00546 · DOI
- Ternette, 2016, Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells, Eur. J. Immunol., 46, 60, 10.1002/eji.201545890 · DOI · Paper page
- Nagler, 2021, Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics, Cell Rep., 35, 10.1016/j.celrep.2021.109305 · DOI · Paper page
- Knierman, 2020, The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein, Cell Rep., 33, 10.1016/j.celrep.2020.108454 · DOI · Paper page
- Parker, 2021, Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells, Cell Rep., 35, 10.1016/j.celrep.2021.109179 · DOI · Paper page
- Becerra-Artiles, 2022, Immunopeptidome Profiling of Human Coronavirus OC43-Infected Cells Identifies CD4 T Cell Epitopes Specific to Seasonal Coronaviruses or Cross-Reactive with SARS-CoV-2, bioRxiv
- Becerra-Artiles, 2019, Naturally processed HLA-DR3-restricted HHV-6B peptides are recognized broadly with polyfunctional and cytotoxic CD4 T-cell responses, Eur. J. Immunol., 49, 1167, 10.1002/eji.201948126 · DOI
- Forlani, 2021, CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens, Mol. Cell. Proteomics, 20, 10.1074/mcp.RA120.002201 · DOI
- Hos, 2022, Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA, Cell Rep., 41, 10.1016/j.celrep.2022.111485 · DOI
- Neuwelt, 2020, Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms, J. Immunother. Cancer, 8
- Wosen, 2018, Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts, Front. Immunol., 9, 2144, 10.3389/fimmu.2018.02144 · DOI · Paper page
- Andreatta, 2017, GibbsCluster: unsupervised clustering and alignment of peptide sequences, Nucleic Acids Res., 45, W458, 10.1093/nar/gkx248 · DOI · Paper page
- Deffrennes, 2001, Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter, J. Immunol., 167, 98, 10.4049/jimmunol.167.1.98 · DOI
- Bruchez, 2020, MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses, Science, 370, 241, 10.1126/science.abb3753 · DOI
- Ovsyannikova, 2003, Naturally processed measles virus peptide eluted from class II HLA-DRB1∗03 recognized by T lymphocytes from human blood, Virology, 312, 495, 10.1016/S0042-6822(03)00281-2 · doi:10.1016/s0042-6822(03)00281-2
- Cassotta, 2020, Deciphering and predicting CD4+ T cell immunodominance of influenza virus hemagglutinin, J. Exp. Med., 217, 10.1084/jem.20200206 · DOI
- Abelin, 2019, Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction, Immunity, 51, 766, 10.1016/j.immuni.2019.08.012 · DOI · Paper page
- Taylor, 2021, MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100116 · DOI
- Lippolis, 2002, Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets, J. Immunol., 169, 5089, 10.4049/jimmunol.169.9.5089 · DOI · Paper page
- Firth, 2020, A putative new SARS-CoV protein, 3c, encoded in an ORF overlapping ORF3a, J. Gen. Virol., 101, 1085, 10.1099/jgv.0.001469 · DOI
- Jungreis, 2021, SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes, Nat. Commun., 12, 2642, 10.1038/s41467-021-22905-7 · DOI · Paper page
- Cagliani, 2020, Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses, Infect. Genet. Evol., 83, 10.1016/j.meegid.2020.104353 · DOI
- Prakash, S., Srivastava, R., Coulon, P.-G., Dhanushkodi, N.R., Chentoufi, A.A., Tifrea, D.F., Edwards, R.A., Figueroa, C., Schubl, S.D., Hsieh, L., et al. Genome-Wide Asymptomatic B-Cell, CD4 and CD8 T-Cell Epitopes, that are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines. SSRN Journal. .
- Kyriakidis, 2021, SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates, NPJ Vaccines, 6, 28, 10.1038/s41541-021-00292-w · DOI · Paper page
- Creech, 2021, SARS-CoV-2 Vaccines, JAMA, 325, 1318, 10.1001/jama.2021.3199 · DOI · Paper page
- Barouch, 2022, Covid-19 Vaccines — Immunity, Variants, Boosters, N. Engl. J. Med., 387, 1011, 10.1056/NEJMra2206573 · DOI · Paper page
- Dai, 2021, Viral targets for vaccines against COVID-19, Nat. Rev. Immunol., 21, 73, 10.1038/s41577-020-00480-0 · DOI · Paper page
- Silva, 2022, Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats, PLoS One, 17, 10.1371/journal.pone.0268434 · DOI
- Weingarten-Gabbay, 2022, HLA-I immunopeptidome profiling of human cells infected with high-containment enveloped viruses, STAR Protoc., 3, 10.1016/j.xpro.2022.101910 · DOI
- Ruiz Cuevas, 2021, Most non-canonical proteins uniquely populate the proteome or immunopeptidome, Cell Rep., 34, 10.1016/j.celrep.2021.108815 · DOI · Paper page
- Stewart, 2022, The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity, bioRxiv
- Ghosh, 2020, β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway, Cell, 183, 1520, 10.1016/j.cell.2020.10.039 · DOI · Paper page
- Chen, 2021, SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway, J. Virol., 95, 10.1128/JVI.00862-21 · DOI
- Gentili, 2023, ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signalling, Nat. Commun., 14, 611, 10.1038/s41467-023-36132-9 · DOI
- Abelin, 2023, Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues, Nat. Commun., 14, 1851, 10.1038/s41467-023-37547-0 · DOI
- Wu, 2020, A new coronavirus associated with human respiratory disease in China, Nature, 579, 265, 10.1038/s41586-020-2008-3 · DOI · Paper page
Cited by
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51959-6 · Cited by 12
Metadata
- Authors
- Weingarten-Gabbay, S., Chen, D.-Y., Sarkizova, S., Taylor, H. B., Gentili, M., Hernandez, G. M., Pearlman, L. R., Bauer, M. R., Rice, C. M., Clauser, K. R., Hacohen, N., Carr, S. A., Abelin, J. G., Saeed, M., & Sabeti, P. C.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 43
- Issue
- 1
- Pages
- 113596
- ISSN
- 2211-1247
- Cited by
- 17
- References
- 15
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The HLA-II immunopeptidome of SARS-CoV-2. https://app.cochat.ai/papers/10.1016/j.celrep.2023.113596
- The paper
- Weingarten-Gabbay, S., Chen, D.-Y., Sarkizova, S., Taylor, H. B., Gentili, M., Hernandez, G. M., Pearlman, L. R., Bauer, M. R., Rice, C. M., Clauser, K. R., Hacohen, N., Carr, S. A., Abelin, J. G., Saeed, M., & Sabeti, P. C. (2024). The HLA-II immunopeptidome of SARS-CoV-2. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.